{"id":390312,"date":"2019-12-12T00:00:00","date_gmt":"2019-12-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2019-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-18T11:37:01","modified_gmt":"2026-04-18T11:37:01","slug":"dlsfon0005-2019-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2019-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Multiple Myeloma | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p><strong>Market Outlook<\/strong><\/p>\n<p>The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet and triplet regimens but also as quadruplets is driving the sales of multiple myeloma drugs. While Celgene\u2019s Revlimid and Janssen \/ Takeda Pharmaceutical\u2019s Velcade remain the cornerstones of therapy for multiple myeloma, emerging agents such as Sanofi \/ ImmunoGen\u2019s <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608552304734625944\">isatuximab<\/gwmw>, Oncopeptides\u2019 Ygalo, Karyopharm Therapeutics\u2019 Xpovio \/ <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608552308926631941\">selinexor<\/gwmw>, BMS \/ Bluebird Bio\u2019s <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608552305996489544\">idecabtagene<\/gwmw> <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608552303634406477\">vicleucel<\/gwmw>\u00a0\/ bb2121, and GlaxoSmithKline\u2019s <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608552306055237499\">belantamab<\/gwmw> <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608552306024605465\">mafodotin<\/gwmw> \/ GSK2857916 are pursuing initial approvals. There is immense clinical and commercial potential to be exploited in multiple myeloma for therapies that have improved efficacy, novel mechanisms of action, and cater to <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608563420394655807\">underserved<\/gwmw> patient segments.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How has the approval of Janssen\u2019s Darzalex and Bristol-Myers Squibb \/ AbbVie\u2019s Empliciti impacted the multiple myeloma market? How important will these agents become over the forecast period?<\/li>\n<li>Revlimid and Velcade are widely used for the current treatment of multiple myeloma, but how will the use of these agents change over the forecast period? What impact will generic entries of these pivotal agents have on the multiple myeloma market?<\/li>\n<li>What are thought leaders\u2019 opinions on agents in Phase III development, such as Sanofi \/ ImmunoGen\u2019s <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608615714130422780\">isatuximab<\/gwmw>, BMS \/ Bluebird Bio\u2019s\u00a0<gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608615719933561295\">idecabtagene<\/gwmw> <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608615710804836169\">vicleucel<\/gwmw>\u00a0\/\u00a0bb2121,\u00a0GlaxoSmithKline\u2019s <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608615717272016187\">belantamab<\/gwmw> <gwmw class=\"ginger-module-highlighter-mistake-type-1\" id=\"gwmw-15854608615711839342721\">mafodotin<\/gwmw> \/\u00a0GSK2857916, and Janssen\u2019s subcutaneous formulation of Darzalex?<\/li>\n<li>What impact will these agents have on the multiple myeloma market? What are the drivers and constraints in the multiple myeloma market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market <gwmw class=\"ginger-module-highlighter-mistake-type-6\" id=\"gwmw-15854608643844166972405\">intelligence providing<\/gwmw> world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390312","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-myeloma","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390312\/revisions"}],"predecessor-version":[{"id":576568,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390312\/revisions\/576568"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}